Mestag awarded £1.5m grant to revolutionise cancer treatment

Quick Summary:

Cambridge-based BioTech company Mestag Therapeutics has been awarded a £1.5 million Transforming Cancer Therapeutics grant.

TLS are believed to enable improved immune cell access to the tumour and drive local immune cell education, leading to a powerful orchestrated anti-tumor response.

MST-0300 is an antibody designed to induce tertiary lymphoid structures in solid tumours in a highly specific and localised fashion.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Jonathan Symcox

Category: InvestingBusiness

Markets: United Kingdom

Topics: MedTech Investment

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-08-29 @ 16:34:59 (2 days ago)

News Timezone: GMT +8:00

News Source URL: businesscloud.co.uk

Language: English

Article Length: 243 words

Reading Time: 2 minutes read

Sentences: 8 lines

Sentence Length: 31 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © BusinessCloud

News ID: 22300548

View Article Analysis

About BusinessCloud

Main Topics: InvestingBusiness

Official Website: businesscloud.co.uk

Year Established: 2016

Headquarters: United Kingdom

News Last Updated: 1 days ago

Coverage Areas: United Kingdom

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #61

Publisher Details

Frequently Asked Questions